APPLICATIONS PUBLISHED 19 NOVEMBER 2003
Published: 1-May-2004
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
The following patent applications are taken from the weekly European Patents Bulletin and give the publication number and date of publication as well as the title of the specification and the applicant. An asterisk denotes that application was made through the International Patent Cooperation Treaty (PCT). Further details on individual patent applications can be obtained from the EPO at Schottenfeldgasse 29, A-1072 Vienna. Tel: +43 1521 260 Fax: +43 1 52126 4492
Topical solution containing a chromane or chromene derivative
Laboratoires Pharmascience 1361854*
Modulated release particles for aerosol delivery
Aeropharm Technology Inc 1361857*
Modulated release particles for aerosol delivery
Aeropharm Technology Inc 1361858*
Modulated release particles for aerosol delivery
Aeropharm Technology Inc 1361859*
Modulated release particles for aerosol delivery
Aeropharm Technology Inc 1361860*
Modulated release particles for aerosol delivery
Aeropharm Technology Inc 1361861*
Liposome-mediated DNA administration
Opperbas Holding 1361862*
Carotenoid-loaded liposomes
Yissum Research Development Company of the Hebrew University of Jerusalem 1361863*
Mucoadhesive pharmaceutical formulations
GW Pharma 1361864*
Cubic liquid crystalline compsns and methods for their preparation
Procter & Gamble 1361865*
Emulsions as solid dosage forms for oral administration
Cima Labs 1361866*
Fibrate-statin combinations with reduced fed-fasted effects
Skyepharma Canada 1361867*
Novel modified release formulation
AstraZeneca 1361868*
Transdermal therapeutic system containing testosterone and method for the production thereof
LTS Lohmann Therapie-Systeme 1361869*
A substance for use in a dietary supplement or for the preparation of a medicament for the treatment of non-insulin dependent diabetes mellitus, hypertension and the metabolic syndrome
Nutri Pharma; Hermansen, Kjeld; Gregersen, Soeren; Jeppesen, Per Bendix 1361870*
Medicament formulation containing a muscarinic antagonist
Boehringer Ingelheim Pharma 1361871*
Novel lysophosphatidic acid receptor agonists and antagonists
University of Virginia Patent Foundation 1361872*
Matrix metalloproteinase inhibitors
Warner-Lambert 1361873*
Treatment of diseases characterised by excessive or insufficient cell death
Neurosearch 1361874*
Novel heterocyclic amide derivatives and their use as dopamine receptor ligands
Aventis Pharmaceuticals 1361875*
Novel cannabimimetic ligands
The University of Connecticut 1361876*
Pharmaceutical dosage forms of epothilones for oral administration
Bristol-Myers Squibb 1361877*
Treatment of Parkinson's disease by the combined action of a compound with neurotrophic activity and compound enhancing the dopamine activity
Neurosearch 1361878*
2,4-disubstituted pyrimidine-5-carboxamide derivatives as KCNQ potassium channel modulators
Bristol-Myers Squibb 1361879*
6-substituted pyrido-pyrimidines
F Hoffmann-La Roche 1361880*
Steroid hormone products and methods for preparing them
Ortho-McNeil Pharmaceutical 1361881*
4-fluoro-N-indan-2-yl benzamide and its use as a pharmaceutical
Aventis Pharma 1361882*
Polynucleotide encoding a novel human potassium channel beta-subunit, K-betam6, expressed highly in the small intestine
Bristol-Myers Squibb 1361883*
Sensitisation of chemotherapeutic agent resistant neoplastic cells with reovirus
Oncolytics Biotech 1361884*
Use of g-GT inhibitors for the treatment of degenerative diseases
GTX Pharmaceuticals; Weiher, Hans 1361885*
Methods and compsns for inhibiting HIV-coreceptor interactions
The Government of the USA, as represented by the Secretary, Department of Health and Human Services 1361886*
Angiogenically effective unit dose of FGF-2 and method of use
Chiron Corp 1361887*
Method of treating neurological diseases
King's College London 1361888*
Novel vaccine
GlaxoSmithKline Biologicals 1361889*
Influenza vaccine formulations for intradermal delivery
GlaxoSmithKline Biologicals 1361890*
Artificial fusion proteins with reduced immunogenicity
Merck Patent 1361891*
Binding domain-immunoglobulin fusion proteins
Genecraft 1362892*
Modified anti-EGFR antibodies with reduced immunogenicity
Merck Patent 1361893*
Use of a polyfunctional active substance mixture as an antagonist against harmful substances contained in tobacco smoke acting as a health protecting agent during smoking
Hecht, Karl; Tech, Egon 1361894*
Terminally-branched polymeric linkers and polymeric conjugates containing the same
Enzon 1361895*
Localised myocardial injection method of treating ischaemic myocardium
Boston Scientific Corp 1361896*
Methods for inhibiting pain
The General Hospital Corp 1361897*
Modulated release particles for aerosol delivery
Aeropharm Technology Inc 1361898*
Devices and methods for the treatment of cancer
Psimedica 1361899*
Method for extracting, fractionating and purifying polyphenol compounds originating from fresh vegetable culls using a high absorption and elution resin
Institut National de la Recherche Agronomique 1362021*
Method for producing macrocyclic ketones
Givaudan 1362023*
Preparation of mandelic acid derivatives
Avecia 13620254*
Polyhalogen-substituted cinnamic acids and cinnamic acid derivatives and a method for producing the same
Bayer 1362025*
Method for producing bis(trifluoromethyl)imido salts
Merck Patent 1362026*
Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenyl amine and their use as pharmaceuticals
Aventis Pharma 1362027*
Isophthalic acid derivatives as matrix metalloproteinase inhibitors
Warner-Lambert 1362028*
Peroxyester preparation method
Atofina 1362029*
Novel benzoylguanidine salt
Boehringer Ingelhiem Pharma 1362030*
Pharmaceutically active piperidine derivatives
Oxford Glycosciences (UK); The Chancellor, Masters and Scholars of the University of Oxford 1362031*
Process of preparing paroxetine and intermediates for use therein
Spurcourt 1362032*
Pyridine matrix metalloproteinase inhibitors
Warner-Lambert 1362033*
Quinoline, isoquinoline and phthalazine derivatives as antagonists of the gonadotropin-releasing hormone
Schering 1362034*
Diaminopyrazole compounds and the use thereof in the oxidative dyeing of keratinous dyeing of keratinous fibres
L'Oreal 1362035*
Process for synthesis of heteroaryl-substituted urea compounds useful as anti-inflammatory agents
Boehringer Ingelheim Pharma 1362037*
Novel alkyl phenylimino-imidazolidine derivatives for treating urinary incontinence
Boehringer Ingelheim Pharma 1362038*
Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands
Aventis Pharmaceuticals 1362039*
Process for the preparation of mesylates of piperazine derivatives
Solvay Pharmaceuticals 1362040*
Aryl carbamate derivatives, preparation and use thereof
Cerep; Centre National de la Recherche Scientifique; Institut National de la Sante et de la Recherche Medicale (INSERM) 1362041*
Cyclic 2-carbonylaminoketones as inhibitors of cruzipain and other cysteine proteases
Amura Therapeutics 1362042*
Lactone compounds as novel photoinitiators
Clariant International 1362043*
Phthalazinone-piperadino-derivatives as PDE4 inhibitors
Altana Pharma 1362044*
2-thiosubstituted imidazole derivatives and the use thereof in the pharmaceutical industry
Merckle 1362045*
Substituted pyrimidine derivatives as ligands of integrin receptors
Abbott 1362046*
Indazolyl-substituted pyrrolidine compounds as kinase inhibitors
Ortho-McNeil Pharmaceutical 1362047*
Triazolo compounds as MMP inhibitors
Warner-Lambert 1362048*
Pyrimidine derivatives for the inhibition of cell proliferation
AstraZeneca 1362050*
Method for purifying 20(S)-camptothecin
Boehringer Ingelheim Pharma 1362051*
Inhibitors of cruzipain and other cysteine proteases
Amura Therapeutics 1362052*
